• FDA approves new formulation, dosage strength of Nuplazid for Parkinson's psychosis

    3 monthes ago - By Healio

    The FDA approved a new capsule dose formulation and tablet strength of Nuplazid to treat hallucinations and delusions associated with Parkinson's disease psychosis, according to a press release.
    The new 34-mg formulation of Nuplazid (pimavanserin, Acadia Pharmaceuticals Inc.) will now be available in a single, small capsule, rather than two 17-mg tablets; thus, minimizing pill burden for patients, according to the release.
    The FDA also approved a 10-mg tablet of pimavanserin that offers an optimized lower dose for patients who receive strong cytochrome 3A4 inhibitors, according to the
    Read more ...